nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—PDE3A—penis—atherosclerosis	0.0261	0.691	CbGeAlD
Anagrelide—PDE3A—cardiovascular system—atherosclerosis	0.00419	0.111	CbGeAlD
Anagrelide—PDE3A—adipose tissue—atherosclerosis	0.0037	0.0981	CbGeAlD
Anagrelide—PDE3A—liver—atherosclerosis	0.00259	0.0688	CbGeAlD
Anagrelide—Flatulence—Lovastatin—atherosclerosis	0.00247	0.00272	CcSEcCtD
Anagrelide—Hypoaesthesia—Niacin—atherosclerosis	0.00246	0.00271	CcSEcCtD
Anagrelide—Malnutrition—Ezetimibe—atherosclerosis	0.00245	0.0027	CcSEcCtD
Anagrelide—Rhinitis—Pravastatin—atherosclerosis	0.00244	0.00268	CcSEcCtD
Anagrelide—Oedema peripheral—Niacin—atherosclerosis	0.00243	0.00268	CcSEcCtD
Anagrelide—Hepatitis—Pravastatin—atherosclerosis	0.00243	0.00268	CcSEcCtD
Anagrelide—Confusional state—Rosuvastatin—atherosclerosis	0.00243	0.00268	CcSEcCtD
Anagrelide—Back pain—Lovastatin—atherosclerosis	0.00242	0.00267	CcSEcCtD
Anagrelide—Hypoaesthesia—Pravastatin—atherosclerosis	0.00242	0.00266	CcSEcCtD
Anagrelide—Flatulence—Ezetimibe—atherosclerosis	0.00242	0.00266	CcSEcCtD
Anagrelide—Pharyngitis—Pravastatin—atherosclerosis	0.00241	0.00266	CcSEcCtD
Anagrelide—Chills—Simvastatin—atherosclerosis	0.00241	0.00266	CcSEcCtD
Anagrelide—Muscle spasms—Lovastatin—atherosclerosis	0.00241	0.00265	CcSEcCtD
Anagrelide—Infection—Rosuvastatin—atherosclerosis	0.00239	0.00264	CcSEcCtD
Anagrelide—Visual impairment—Niacin—atherosclerosis	0.00238	0.00262	CcSEcCtD
Anagrelide—Alopecia—Simvastatin—atherosclerosis	0.00238	0.00262	CcSEcCtD
Anagrelide—Back pain—Ezetimibe—atherosclerosis	0.00237	0.00262	CcSEcCtD
Anagrelide—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00236	0.0026	CcSEcCtD
Anagrelide—Muscle spasms—Ezetimibe—atherosclerosis	0.00236	0.0026	CcSEcCtD
Anagrelide—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.00236	0.0026	CcSEcCtD
Anagrelide—Vision blurred—Lovastatin—atherosclerosis	0.00236	0.0026	CcSEcCtD
Anagrelide—Visual impairment—Pravastatin—atherosclerosis	0.00234	0.00258	CcSEcCtD
Anagrelide—Ill-defined disorder—Lovastatin—atherosclerosis	0.00232	0.00256	CcSEcCtD
Anagrelide—Eye disorder—Niacin—atherosclerosis	0.00231	0.00254	CcSEcCtD
Anagrelide—Flatulence—Simvastatin—atherosclerosis	0.00231	0.00254	CcSEcCtD
Anagrelide—Tinnitus—Niacin—atherosclerosis	0.0023	0.00254	CcSEcCtD
Anagrelide—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00228	0.00251	CcSEcCtD
Anagrelide—Anaemia—Ezetimibe—atherosclerosis	0.00227	0.0025	CcSEcCtD
Anagrelide—Tinnitus—Pravastatin—atherosclerosis	0.00227	0.0025	CcSEcCtD
Anagrelide—Malaise—Lovastatin—atherosclerosis	0.00226	0.00249	CcSEcCtD
Anagrelide—Cardiac disorder—Pravastatin—atherosclerosis	0.00226	0.00249	CcSEcCtD
Anagrelide—Muscle spasms—Simvastatin—atherosclerosis	0.00225	0.00248	CcSEcCtD
Anagrelide—Chills—Niacin—atherosclerosis	0.00222	0.00244	CcSEcCtD
Anagrelide—Malaise—Ezetimibe—atherosclerosis	0.00221	0.00244	CcSEcCtD
Anagrelide—Vision blurred—Simvastatin—atherosclerosis	0.00221	0.00243	CcSEcCtD
Anagrelide—Arrhythmia—Niacin—atherosclerosis	0.00221	0.00243	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.0022	0.00242	CcSEcCtD
Anagrelide—Alopecia—Niacin—atherosclerosis	0.00218	0.0024	CcSEcCtD
Anagrelide—Chills—Pravastatin—atherosclerosis	0.00218	0.0024	CcSEcCtD
Anagrelide—Insomnia—Rosuvastatin—atherosclerosis	0.00218	0.0024	CcSEcCtD
Anagrelide—Ill-defined disorder—Simvastatin—atherosclerosis	0.00217	0.00239	CcSEcCtD
Anagrelide—Arrhythmia—Pravastatin—atherosclerosis	0.00217	0.00239	CcSEcCtD
Anagrelide—Palpitations—Ezetimibe—atherosclerosis	0.00217	0.00239	CcSEcCtD
Anagrelide—Paraesthesia—Rosuvastatin—atherosclerosis	0.00216	0.00238	CcSEcCtD
Anagrelide—Anaemia—Simvastatin—atherosclerosis	0.00216	0.00238	CcSEcCtD
Anagrelide—Malnutrition—Niacin—atherosclerosis	0.00215	0.00237	CcSEcCtD
Anagrelide—Alopecia—Pravastatin—atherosclerosis	0.00215	0.00237	CcSEcCtD
Anagrelide—Cough—Ezetimibe—atherosclerosis	0.00214	0.00236	CcSEcCtD
Anagrelide—Myalgia—Lovastatin—atherosclerosis	0.00213	0.00235	CcSEcCtD
Anagrelide—Chest pain—Lovastatin—atherosclerosis	0.00213	0.00235	CcSEcCtD
Anagrelide—Arthralgia—Lovastatin—atherosclerosis	0.00213	0.00235	CcSEcCtD
Anagrelide—Dyspepsia—Rosuvastatin—atherosclerosis	0.00212	0.00234	CcSEcCtD
Anagrelide—Hypertension—Ezetimibe—atherosclerosis	0.00212	0.00233	CcSEcCtD
Anagrelide—Flatulence—Niacin—atherosclerosis	0.00212	0.00233	CcSEcCtD
Anagrelide—Malaise—Simvastatin—atherosclerosis	0.00211	0.00233	CcSEcCtD
Anagrelide—Tension—Niacin—atherosclerosis	0.00211	0.00232	CcSEcCtD
Anagrelide—Discomfort—Lovastatin—atherosclerosis	0.00211	0.00232	CcSEcCtD
Anagrelide—Arthralgia—Ezetimibe—atherosclerosis	0.00209	0.0023	CcSEcCtD
Anagrelide—Myalgia—Ezetimibe—atherosclerosis	0.00209	0.0023	CcSEcCtD
Anagrelide—Chest pain—Ezetimibe—atherosclerosis	0.00209	0.0023	CcSEcCtD
Anagrelide—Nervousness—Niacin—atherosclerosis	0.00209	0.0023	CcSEcCtD
Anagrelide—Flatulence—Pravastatin—atherosclerosis	0.00209	0.0023	CcSEcCtD
Anagrelide—Dry mouth—Lovastatin—atherosclerosis	0.00208	0.0023	CcSEcCtD
Anagrelide—Tension—Pravastatin—atherosclerosis	0.00208	0.00229	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00208	0.00229	CcSEcCtD
Anagrelide—Muscle spasms—Niacin—atherosclerosis	0.00207	0.00228	CcSEcCtD
Anagrelide—Discomfort—Ezetimibe—atherosclerosis	0.00206	0.00227	CcSEcCtD
Anagrelide—Pain—Rosuvastatin—atherosclerosis	0.00206	0.00227	CcSEcCtD
Anagrelide—Constipation—Rosuvastatin—atherosclerosis	0.00206	0.00227	CcSEcCtD
Anagrelide—Confusional state—Lovastatin—atherosclerosis	0.00206	0.00227	CcSEcCtD
Anagrelide—Nervousness—Pravastatin—atherosclerosis	0.00206	0.00226	CcSEcCtD
Anagrelide—Dry mouth—Ezetimibe—atherosclerosis	0.00204	0.00225	CcSEcCtD
Anagrelide—Muscle spasms—Pravastatin—atherosclerosis	0.00203	0.00224	CcSEcCtD
Anagrelide—Infection—Lovastatin—atherosclerosis	0.00203	0.00223	CcSEcCtD
Anagrelide—Vision blurred—Niacin—atherosclerosis	0.00203	0.00223	CcSEcCtD
Anagrelide—Confusional state—Ezetimibe—atherosclerosis	0.00202	0.00222	CcSEcCtD
Anagrelide—Thrombocytopenia—Lovastatin—atherosclerosis	0.002	0.0022	CcSEcCtD
Anagrelide—Vision blurred—Pravastatin—atherosclerosis	0.00199	0.0022	CcSEcCtD
Anagrelide—Arthralgia—Simvastatin—atherosclerosis	0.00199	0.0022	CcSEcCtD
Anagrelide—Chest pain—Simvastatin—atherosclerosis	0.00199	0.0022	CcSEcCtD
Anagrelide—Myalgia—Simvastatin—atherosclerosis	0.00199	0.0022	CcSEcCtD
Anagrelide—Infection—Ezetimibe—atherosclerosis	0.00199	0.00219	CcSEcCtD
Anagrelide—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00199	0.00219	CcSEcCtD
Anagrelide—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00197	0.00217	CcSEcCtD
Anagrelide—Discomfort—Simvastatin—atherosclerosis	0.00197	0.00217	CcSEcCtD
Anagrelide—Nervous system disorder—Ezetimibe—atherosclerosis	0.00196	0.00216	CcSEcCtD
Anagrelide—Ill-defined disorder—Pravastatin—atherosclerosis	0.00196	0.00216	CcSEcCtD
Anagrelide—Thrombocytopenia—Ezetimibe—atherosclerosis	0.00196	0.00216	CcSEcCtD
Anagrelide—Anaemia—Pravastatin—atherosclerosis	0.00196	0.00215	CcSEcCtD
Anagrelide—Anorexia—Lovastatin—atherosclerosis	0.00195	0.00214	CcSEcCtD
Anagrelide—Skin disorder—Ezetimibe—atherosclerosis	0.00195	0.00214	CcSEcCtD
Anagrelide—Syncope—Niacin—atherosclerosis	0.00193	0.00212	CcSEcCtD
Anagrelide—Confusional state—Simvastatin—atherosclerosis	0.00193	0.00212	CcSEcCtD
Anagrelide—Urticaria—Rosuvastatin—atherosclerosis	0.00191	0.00211	CcSEcCtD
Anagrelide—Oedema—Simvastatin—atherosclerosis	0.00191	0.0021	CcSEcCtD
Anagrelide—Malaise—Pravastatin—atherosclerosis	0.00191	0.0021	CcSEcCtD
Anagrelide—Abdominal pain—Rosuvastatin—atherosclerosis	0.00191	0.0021	CcSEcCtD
Anagrelide—Palpitations—Niacin—atherosclerosis	0.0019	0.00209	CcSEcCtD
Anagrelide—Infection—Simvastatin—atherosclerosis	0.0019	0.00209	CcSEcCtD
Anagrelide—Loss of consciousness—Niacin—atherosclerosis	0.00189	0.00208	CcSEcCtD
Anagrelide—Cough—Niacin—atherosclerosis	0.00188	0.00207	CcSEcCtD
Anagrelide—Thrombocytopenia—Simvastatin—atherosclerosis	0.00187	0.00206	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00186	0.00205	CcSEcCtD
Anagrelide—Insomnia—Lovastatin—atherosclerosis	0.00185	0.00203	CcSEcCtD
Anagrelide—Cough—Pravastatin—atherosclerosis	0.00185	0.00203	CcSEcCtD
Anagrelide—Paraesthesia—Lovastatin—atherosclerosis	0.00183	0.00202	CcSEcCtD
Anagrelide—Arthralgia—Niacin—atherosclerosis	0.00183	0.00202	CcSEcCtD
Anagrelide—Myalgia—Niacin—atherosclerosis	0.00183	0.00202	CcSEcCtD
Anagrelide—Hypertension—Pravastatin—atherosclerosis	0.00183	0.00201	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00183	0.00201	CcSEcCtD
Anagrelide—Anorexia—Simvastatin—atherosclerosis	0.00182	0.00201	CcSEcCtD
Anagrelide—Dyspnoea—Lovastatin—atherosclerosis	0.00182	0.00201	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00182	0.002	CcSEcCtD
Anagrelide—Insomnia—Ezetimibe—atherosclerosis	0.00181	0.002	CcSEcCtD
Anagrelide—Myalgia—Pravastatin—atherosclerosis	0.0018	0.00198	CcSEcCtD
Anagrelide—Arthralgia—Pravastatin—atherosclerosis	0.0018	0.00198	CcSEcCtD
Anagrelide—Chest pain—Pravastatin—atherosclerosis	0.0018	0.00198	CcSEcCtD
Anagrelide—Paraesthesia—Ezetimibe—atherosclerosis	0.0018	0.00198	CcSEcCtD
Anagrelide—Dyspepsia—Lovastatin—atherosclerosis	0.0018	0.00198	CcSEcCtD
Anagrelide—Dry mouth—Niacin—atherosclerosis	0.00179	0.00197	CcSEcCtD
Anagrelide—Dyspnoea—Ezetimibe—atherosclerosis	0.00179	0.00197	CcSEcCtD
Anagrelide—Discomfort—Pravastatin—atherosclerosis	0.00178	0.00196	CcSEcCtD
Anagrelide—Decreased appetite—Lovastatin—atherosclerosis	0.00178	0.00196	CcSEcCtD
Anagrelide—Dyspepsia—Ezetimibe—atherosclerosis	0.00176	0.00194	CcSEcCtD
Anagrelide—Fatigue—Lovastatin—atherosclerosis	0.00176	0.00194	CcSEcCtD
Anagrelide—Oedema—Niacin—atherosclerosis	0.00175	0.00193	CcSEcCtD
Anagrelide—Constipation—Lovastatin—atherosclerosis	0.00175	0.00192	CcSEcCtD
Anagrelide—Pain—Lovastatin—atherosclerosis	0.00175	0.00192	CcSEcCtD
Anagrelide—Confusional state—Pravastatin—atherosclerosis	0.00174	0.00192	CcSEcCtD
Anagrelide—Decreased appetite—Ezetimibe—atherosclerosis	0.00174	0.00192	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00174	0.00192	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00173	0.0019	CcSEcCtD
Anagrelide—Asthenia—Rosuvastatin—atherosclerosis	0.00173	0.0019	CcSEcCtD
Anagrelide—Insomnia—Simvastatin—atherosclerosis	0.00173	0.0019	CcSEcCtD
Anagrelide—Oedema—Pravastatin—atherosclerosis	0.00173	0.0019	CcSEcCtD
Anagrelide—Fatigue—Ezetimibe—atherosclerosis	0.00173	0.0019	CcSEcCtD
Anagrelide—Shock—Niacin—atherosclerosis	0.00173	0.0019	CcSEcCtD
Anagrelide—Infection—Pravastatin—atherosclerosis	0.00172	0.00189	CcSEcCtD
Anagrelide—Paraesthesia—Simvastatin—atherosclerosis	0.00172	0.00189	CcSEcCtD
Anagrelide—Pain—Ezetimibe—atherosclerosis	0.00171	0.00189	CcSEcCtD
Anagrelide—Constipation—Ezetimibe—atherosclerosis	0.00171	0.00189	CcSEcCtD
Anagrelide—Tachycardia—Niacin—atherosclerosis	0.00171	0.00189	CcSEcCtD
Anagrelide—Pruritus—Rosuvastatin—atherosclerosis	0.00171	0.00188	CcSEcCtD
Anagrelide—Skin disorder—Niacin—atherosclerosis	0.0017	0.00188	CcSEcCtD
Anagrelide—Dyspnoea—Simvastatin—atherosclerosis	0.0017	0.00188	CcSEcCtD
Anagrelide—Hyperhidrosis—Niacin—atherosclerosis	0.0017	0.00187	CcSEcCtD
Anagrelide—Thrombocytopenia—Pravastatin—atherosclerosis	0.00169	0.00186	CcSEcCtD
Anagrelide—Feeling abnormal—Lovastatin—atherosclerosis	0.00168	0.00185	CcSEcCtD
Anagrelide—Dyspepsia—Simvastatin—atherosclerosis	0.00168	0.00185	CcSEcCtD
Anagrelide—Anorexia—Niacin—atherosclerosis	0.00167	0.00184	CcSEcCtD
Anagrelide—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00167	0.00184	CcSEcCtD
Anagrelide—Hyperhidrosis—Pravastatin—atherosclerosis	0.00167	0.00184	CcSEcCtD
Anagrelide—Decreased appetite—Simvastatin—atherosclerosis	0.00166	0.00183	CcSEcCtD
Anagrelide—Feeling abnormal—Ezetimibe—atherosclerosis	0.00165	0.00182	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00165	0.00182	CcSEcCtD
Anagrelide—Diarrhoea—Rosuvastatin—atherosclerosis	0.00165	0.00182	CcSEcCtD
Anagrelide—Fatigue—Simvastatin—atherosclerosis	0.00165	0.00181	CcSEcCtD
Anagrelide—Anorexia—Pravastatin—atherosclerosis	0.00165	0.00181	CcSEcCtD
Anagrelide—Hypotension—Niacin—atherosclerosis	0.00164	0.00181	CcSEcCtD
Anagrelide—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00164	0.0018	CcSEcCtD
Anagrelide—Pain—Simvastatin—atherosclerosis	0.00163	0.0018	CcSEcCtD
Anagrelide—Constipation—Simvastatin—atherosclerosis	0.00163	0.0018	CcSEcCtD
Anagrelide—Urticaria—Lovastatin—atherosclerosis	0.00162	0.00179	CcSEcCtD
Anagrelide—Body temperature increased—Lovastatin—atherosclerosis	0.00161	0.00178	CcSEcCtD
Anagrelide—Abdominal pain—Lovastatin—atherosclerosis	0.00161	0.00178	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Niacin—atherosclerosis	0.0016	0.00176	CcSEcCtD
Anagrelide—Dizziness—Rosuvastatin—atherosclerosis	0.00159	0.00176	CcSEcCtD
Anagrelide—Urticaria—Ezetimibe—atherosclerosis	0.00159	0.00175	CcSEcCtD
Anagrelide—Insomnia—Niacin—atherosclerosis	0.00159	0.00175	CcSEcCtD
Anagrelide—Abdominal pain—Ezetimibe—atherosclerosis	0.00158	0.00174	CcSEcCtD
Anagrelide—Body temperature increased—Ezetimibe—atherosclerosis	0.00158	0.00174	CcSEcCtD
Anagrelide—Paraesthesia—Niacin—atherosclerosis	0.00158	0.00173	CcSEcCtD
Anagrelide—Feeling abnormal—Simvastatin—atherosclerosis	0.00157	0.00173	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00157	0.00173	CcSEcCtD
Anagrelide—Dyspnoea—Niacin—atherosclerosis	0.00156	0.00172	CcSEcCtD
Anagrelide—Gastrointestinal pain—Simvastatin—atherosclerosis	0.00156	0.00172	CcSEcCtD
Anagrelide—Insomnia—Pravastatin—atherosclerosis	0.00156	0.00172	CcSEcCtD
Anagrelide—Somnolence—Niacin—atherosclerosis	0.00156	0.00172	CcSEcCtD
Anagrelide—Paraesthesia—Pravastatin—atherosclerosis	0.00155	0.00171	CcSEcCtD
Anagrelide—Dyspepsia—Niacin—atherosclerosis	0.00154	0.0017	CcSEcCtD
Anagrelide—Dyspnoea—Pravastatin—atherosclerosis	0.00154	0.0017	CcSEcCtD
Anagrelide—Decreased appetite—Niacin—atherosclerosis	0.00153	0.00168	CcSEcCtD
Anagrelide—Dyspepsia—Pravastatin—atherosclerosis	0.00152	0.00167	CcSEcCtD
Anagrelide—Rash—Rosuvastatin—atherosclerosis	0.00152	0.00167	CcSEcCtD
Anagrelide—Dermatitis—Rosuvastatin—atherosclerosis	0.00152	0.00167	CcSEcCtD
Anagrelide—Urticaria—Simvastatin—atherosclerosis	0.00152	0.00167	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Niacin—atherosclerosis	0.00151	0.00167	CcSEcCtD
Anagrelide—Body temperature increased—Simvastatin—atherosclerosis	0.00151	0.00166	CcSEcCtD
Anagrelide—Abdominal pain—Simvastatin—atherosclerosis	0.00151	0.00166	CcSEcCtD
Anagrelide—Headache—Rosuvastatin—atherosclerosis	0.00151	0.00166	CcSEcCtD
Anagrelide—Decreased appetite—Pravastatin—atherosclerosis	0.0015	0.00165	CcSEcCtD
Anagrelide—Pain—Niacin—atherosclerosis	0.0015	0.00165	CcSEcCtD
Anagrelide—Fatigue—Pravastatin—atherosclerosis	0.00149	0.00164	CcSEcCtD
Anagrelide—Constipation—Pravastatin—atherosclerosis	0.00148	0.00163	CcSEcCtD
Anagrelide—Pain—Pravastatin—atherosclerosis	0.00148	0.00163	CcSEcCtD
Anagrelide—Asthenia—Lovastatin—atherosclerosis	0.00147	0.00161	CcSEcCtD
Anagrelide—Pruritus—Lovastatin—atherosclerosis	0.00145	0.00159	CcSEcCtD
Anagrelide—Asthenia—Ezetimibe—atherosclerosis	0.00144	0.00158	CcSEcCtD
Anagrelide—Gastrointestinal pain—Niacin—atherosclerosis	0.00143	0.00158	CcSEcCtD
Anagrelide—Nausea—Rosuvastatin—atherosclerosis	0.00143	0.00158	CcSEcCtD
Anagrelide—Feeling abnormal—Pravastatin—atherosclerosis	0.00142	0.00157	CcSEcCtD
Anagrelide—Pruritus—Ezetimibe—atherosclerosis	0.00142	0.00156	CcSEcCtD
Anagrelide—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00141	0.00156	CcSEcCtD
Anagrelide—Diarrhoea—Lovastatin—atherosclerosis	0.0014	0.00154	CcSEcCtD
Anagrelide—Urticaria—Niacin—atherosclerosis	0.00139	0.00153	CcSEcCtD
Anagrelide—Abdominal pain—Niacin—atherosclerosis	0.00139	0.00153	CcSEcCtD
Anagrelide—Body temperature increased—Niacin—atherosclerosis	0.00139	0.00153	CcSEcCtD
Anagrelide—Urticaria—Pravastatin—atherosclerosis	0.00137	0.00151	CcSEcCtD
Anagrelide—Asthenia—Simvastatin—atherosclerosis	0.00137	0.00151	CcSEcCtD
Anagrelide—Diarrhoea—Ezetimibe—atherosclerosis	0.00137	0.00151	CcSEcCtD
Anagrelide—Abdominal pain—Pravastatin—atherosclerosis	0.00137	0.0015	CcSEcCtD
Anagrelide—Body temperature increased—Pravastatin—atherosclerosis	0.00137	0.0015	CcSEcCtD
Anagrelide—Pruritus—Simvastatin—atherosclerosis	0.00135	0.00149	CcSEcCtD
Anagrelide—Dizziness—Lovastatin—atherosclerosis	0.00135	0.00149	CcSEcCtD
Anagrelide—Dizziness—Ezetimibe—atherosclerosis	0.00132	0.00146	CcSEcCtD
Anagrelide—Diarrhoea—Simvastatin—atherosclerosis	0.00131	0.00144	CcSEcCtD
Anagrelide—Vomiting—Lovastatin—atherosclerosis	0.0013	0.00143	CcSEcCtD
Anagrelide—Rash—Lovastatin—atherosclerosis	0.00129	0.00142	CcSEcCtD
Anagrelide—Dermatitis—Lovastatin—atherosclerosis	0.00129	0.00142	CcSEcCtD
Anagrelide—Headache—Lovastatin—atherosclerosis	0.00128	0.00141	CcSEcCtD
Anagrelide—Vomiting—Ezetimibe—atherosclerosis	0.00127	0.0014	CcSEcCtD
Anagrelide—Dizziness—Simvastatin—atherosclerosis	0.00126	0.00139	CcSEcCtD
Anagrelide—Rash—Ezetimibe—atherosclerosis	0.00126	0.00139	CcSEcCtD
Anagrelide—Dermatitis—Ezetimibe—atherosclerosis	0.00126	0.00139	CcSEcCtD
Anagrelide—Asthenia—Niacin—atherosclerosis	0.00126	0.00139	CcSEcCtD
Anagrelide—Headache—Ezetimibe—atherosclerosis	0.00126	0.00138	CcSEcCtD
Anagrelide—Pruritus—Niacin—atherosclerosis	0.00124	0.00137	CcSEcCtD
Anagrelide—Asthenia—Pravastatin—atherosclerosis	0.00124	0.00136	CcSEcCtD
Anagrelide—Pruritus—Pravastatin—atherosclerosis	0.00122	0.00135	CcSEcCtD
Anagrelide—Vomiting—Simvastatin—atherosclerosis	0.00121	0.00134	CcSEcCtD
Anagrelide—Nausea—Lovastatin—atherosclerosis	0.00121	0.00134	CcSEcCtD
Anagrelide—Rash—Simvastatin—atherosclerosis	0.0012	0.00133	CcSEcCtD
Anagrelide—Dermatitis—Simvastatin—atherosclerosis	0.0012	0.00133	CcSEcCtD
Anagrelide—Diarrhoea—Niacin—atherosclerosis	0.0012	0.00132	CcSEcCtD
Anagrelide—Headache—Simvastatin—atherosclerosis	0.0012	0.00132	CcSEcCtD
Anagrelide—Nausea—Ezetimibe—atherosclerosis	0.00119	0.00131	CcSEcCtD
Anagrelide—Diarrhoea—Pravastatin—atherosclerosis	0.00118	0.0013	CcSEcCtD
Anagrelide—Dizziness—Niacin—atherosclerosis	0.00116	0.00128	CcSEcCtD
Anagrelide—CYP1A2—liver—atherosclerosis	0.00115	0.0305	CbGeAlD
Anagrelide—Dizziness—Pravastatin—atherosclerosis	0.00114	0.00126	CcSEcCtD
Anagrelide—Nausea—Simvastatin—atherosclerosis	0.00113	0.00125	CcSEcCtD
Anagrelide—Vomiting—Niacin—atherosclerosis	0.00112	0.00123	CcSEcCtD
Anagrelide—Rash—Niacin—atherosclerosis	0.00111	0.00122	CcSEcCtD
Anagrelide—Dermatitis—Niacin—atherosclerosis	0.00111	0.00122	CcSEcCtD
Anagrelide—Headache—Niacin—atherosclerosis	0.0011	0.00121	CcSEcCtD
Anagrelide—Vomiting—Pravastatin—atherosclerosis	0.0011	0.00121	CcSEcCtD
Anagrelide—Rash—Pravastatin—atherosclerosis	0.00109	0.0012	CcSEcCtD
Anagrelide—Dermatitis—Pravastatin—atherosclerosis	0.00109	0.0012	CcSEcCtD
Anagrelide—Headache—Pravastatin—atherosclerosis	0.00108	0.00119	CcSEcCtD
Anagrelide—Nausea—Niacin—atherosclerosis	0.00104	0.00115	CcSEcCtD
Anagrelide—Nausea—Pravastatin—atherosclerosis	0.00103	0.00113	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—AHR—atherosclerosis	0.000597	0.011	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—AHR—atherosclerosis	0.000597	0.011	CbGpPWpGaD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27A1—atherosclerosis	0.000583	0.0107	CbGpPWpGaD
Anagrelide—CYP1A2—Oxidation by Cytochrome P450—CYP27A1—atherosclerosis	0.000575	0.0106	CbGpPWpGaD
Anagrelide—CYP1A2—Arachidonic acid metabolism—ALOX5—atherosclerosis	0.000544	0.01	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—F3—atherosclerosis	0.000514	0.00945	CbGpPWpGaD
Anagrelide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—atherosclerosis	0.000513	0.00945	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—CYP7A1—atherosclerosis	0.000511	0.00941	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—F5—atherosclerosis	0.000487	0.00896	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—SELP—atherosclerosis	0.000487	0.00896	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—CYP27A1—atherosclerosis	0.000473	0.0087	CbGpPWpGaD
Anagrelide—CYP1A2—Melatonin metabolism and effects—EDN1—atherosclerosis	0.000471	0.00868	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—CLU—atherosclerosis	0.000464	0.00855	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—HRH1—atherosclerosis	0.000455	0.00838	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—THBD—atherosclerosis	0.000437	0.00804	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—SELE—atherosclerosis	0.000414	0.00762	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—HRH1—atherosclerosis	0.000414	0.00761	CbGpPWpGaD
Anagrelide—CYP1A2—Estrogen Receptor Pathway—STAT3—atherosclerosis	0.000389	0.00716	CbGpPWpGaD
Anagrelide—CYP1A2—Melatonin metabolism and effects—APOE—atherosclerosis	0.000383	0.00706	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—VWF—atherosclerosis	0.000369	0.00679	CbGpPWpGaD
Anagrelide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—atherosclerosis	0.000356	0.00655	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—F7—atherosclerosis	0.000352	0.00648	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—LPL—atherosclerosis	0.000316	0.00582	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PLAT—atherosclerosis	0.000314	0.00577	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—CD36—atherosclerosis	0.0003	0.00553	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCL4—atherosclerosis	0.000299	0.0055	CbGpPWpGaD
Anagrelide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—atherosclerosis	0.000294	0.00541	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—UTS2—atherosclerosis	0.000293	0.0054	CbGpPWpGaD
Anagrelide—CYP1A2—Arachidonic acid metabolism—GPX1—atherosclerosis	0.000289	0.00531	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CASR—atherosclerosis	0.000281	0.00518	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—KNG1—atherosclerosis	0.000275	0.00507	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PLAUR—atherosclerosis	0.000273	0.00502	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP7A1—atherosclerosis	0.000272	0.005	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP7A1—atherosclerosis	0.000268	0.00493	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PLG—atherosclerosis	0.000267	0.00491	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—UTS2—atherosclerosis	0.000267	0.00491	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CNR2—atherosclerosis	0.000262	0.00481	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—SOD1—atherosclerosis	0.000256	0.00471	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CX3CR1—atherosclerosis	0.000256	0.0047	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CASR—atherosclerosis	0.000256	0.0047	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—atherosclerosis	0.000253	0.00466	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP27A1—atherosclerosis	0.000251	0.00462	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CX3CL1—atherosclerosis	0.000251	0.00461	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP27A1—atherosclerosis	0.000248	0.00456	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HRH1—atherosclerosis	0.000244	0.0045	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IGF2—atherosclerosis	0.000243	0.00447	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CNR2—atherosclerosis	0.000238	0.00437	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—APOB—atherosclerosis	0.000236	0.00434	CbGpPWpGaD
Anagrelide—CYP1A2—Melatonin metabolism and effects—NFKB1—atherosclerosis	0.000228	0.0042	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PRKCG—atherosclerosis	0.000219	0.00403	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—CD36—atherosclerosis	0.000214	0.00394	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCL3—atherosclerosis	0.000204	0.00376	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CCR2—atherosclerosis	0.000203	0.00374	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—EDNRA—atherosclerosis	0.000203	0.00374	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—GHRL—atherosclerosis	0.000198	0.00365	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PDGFB—atherosclerosis	0.000197	0.00363	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—MMP1—atherosclerosis	0.000195	0.00359	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—GSTM1—atherosclerosis	0.000192	0.00353	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APOA4—atherosclerosis	0.000192	0.00353	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—atherosclerosis	0.000189	0.00349	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—CAV1—atherosclerosis	0.000187	0.00344	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—APOA1—atherosclerosis	0.000187	0.00343	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCR2—atherosclerosis	0.000185	0.0034	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—EDNRA—atherosclerosis	0.000185	0.0034	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—atherosclerosis	0.000182	0.00334	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—GHRL—atherosclerosis	0.00018	0.00331	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LDLRAP1—atherosclerosis	0.000179	0.00329	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—F2—atherosclerosis	0.000178	0.00328	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCL4—atherosclerosis	0.000177	0.00325	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—NOS2—atherosclerosis	0.000176	0.00324	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—KNG1—atherosclerosis	0.000174	0.0032	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AGTR1—atherosclerosis	0.000173	0.00318	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3CG—atherosclerosis	0.00017	0.00313	CbGpPWpGaD
Anagrelide—CYP1A2—Arachidonic acid metabolism—PTGS2—atherosclerosis	0.00017	0.00313	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—atherosclerosis	0.000169	0.00311	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PLTP—atherosclerosis	0.000168	0.00309	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APOA2—atherosclerosis	0.000165	0.00304	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—KNG1—atherosclerosis	0.000158	0.00291	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—atherosclerosis	0.000158	0.0029	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—UTS2—atherosclerosis	0.000157	0.0029	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AGTR1—atherosclerosis	0.000157	0.00289	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IGF1—atherosclerosis	0.000156	0.00287	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CX3CR1—atherosclerosis	0.000151	0.00278	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CASR—atherosclerosis	0.000151	0.00278	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—SERPINE1—atherosclerosis	0.000148	0.00273	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CX3CL1—atherosclerosis	0.000148	0.00272	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—ALB—atherosclerosis	0.000148	0.00272	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—EDN1—atherosclerosis	0.000147	0.0027	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ABCG8—atherosclerosis	0.000146	0.00268	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LTA4H—atherosclerosis	0.000146	0.00268	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CCL5—atherosclerosis	0.000146	0.00268	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—atherosclerosis	0.000143	0.00263	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—NOS3—atherosclerosis	0.000141	0.0026	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CNR2—atherosclerosis	0.00014	0.00258	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—MMP3—atherosclerosis	0.00014	0.00258	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PRKCG—atherosclerosis	0.000138	0.00255	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—EDN1—atherosclerosis	0.000133	0.00245	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCL5—atherosclerosis	0.000132	0.00243	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—atherosclerosis	0.000131	0.00242	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PRKCG—atherosclerosis	0.000126	0.00231	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VWF—atherosclerosis	0.000125	0.0023	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APOC3—atherosclerosis	0.000124	0.00229	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LDLR—atherosclerosis	0.000124	0.00227	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—atherosclerosis	0.000123	0.00226	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—atherosclerosis	0.000123	0.00226	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AGT—atherosclerosis	0.000122	0.00224	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCL3—atherosclerosis	0.000121	0.00222	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NCF1—atherosclerosis	0.000116	0.00213	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ABCG1—atherosclerosis	0.000115	0.00212	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—F2—atherosclerosis	0.000112	0.00207	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTM1—atherosclerosis	0.000112	0.00206	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTM1—atherosclerosis	0.000111	0.00204	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AGT—atherosclerosis	0.000111	0.00203	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EDNRA—atherosclerosis	0.000109	0.00201	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCR2—atherosclerosis	0.000109	0.00201	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CYBA—atherosclerosis	0.000109	0.002	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LCAT—atherosclerosis	0.000108	0.00199	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—FABP4—atherosclerosis	0.000108	0.00199	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CG—atherosclerosis	0.000108	0.00198	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PARP1—atherosclerosis	0.000106	0.00196	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PLAT—atherosclerosis	0.000106	0.00196	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GHRL—atherosclerosis	0.000106	0.00196	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOA4—atherosclerosis	0.000106	0.00195	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP7A1—atherosclerosis	0.000104	0.00192	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—F2—atherosclerosis	0.000102	0.00188	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—VEGFA—atherosclerosis	0.000102	0.00187	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CG—atherosclerosis	9.77e-05	0.0018	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP27A1—atherosclerosis	9.64e-05	0.00177	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—MAPK3—atherosclerosis	9.64e-05	0.00177	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—TGFB1—atherosclerosis	9.35e-05	0.00172	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KNG1—atherosclerosis	9.33e-05	0.00172	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AGTR1—atherosclerosis	9.28e-05	0.00171	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALOX5AP—atherosclerosis	9.14e-05	0.00168	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—atherosclerosis	9.14e-05	0.00168	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G2A—atherosclerosis	9.14e-05	0.00168	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOA2—atherosclerosis	9.14e-05	0.00168	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCL2—atherosclerosis	9.1e-05	0.00168	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PLG—atherosclerosis	9.04e-05	0.00166	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ABCG5—atherosclerosis	9.03e-05	0.00166	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LPA—atherosclerosis	8.72e-05	0.00161	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SOCS3—atherosclerosis	8.56e-05	0.00158	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOA5—atherosclerosis	8.36e-05	0.00154	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MMP3—atherosclerosis	8.27e-05	0.00152	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IGF2—atherosclerosis	8.23e-05	0.00152	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G1B—atherosclerosis	8.05e-05	0.00148	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APOB—atherosclerosis	7.99e-05	0.00147	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LDLRAP1—atherosclerosis	7.95e-05	0.00146	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CXCL8—atherosclerosis	7.93e-05	0.00146	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EDN1—atherosclerosis	7.87e-05	0.00145	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCL5—atherosclerosis	7.81e-05	0.00144	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALOX5—atherosclerosis	7.77e-05	0.00143	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LPL—atherosclerosis	7.63e-05	0.0014	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLTP—atherosclerosis	7.48e-05	0.00138	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PRKCG—atherosclerosis	7.42e-05	0.00137	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SPP1—atherosclerosis	7.23e-05	0.00133	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CXCL8—atherosclerosis	7.2e-05	0.00132	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—atherosclerosis	6.93e-05	0.00128	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOC3—atherosclerosis	6.89e-05	0.00127	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LDLR—atherosclerosis	6.84e-05	0.00126	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PDGFB—atherosclerosis	6.69e-05	0.00123	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CETP—atherosclerosis	6.68e-05	0.00123	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AGT—atherosclerosis	6.53e-05	0.0012	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—AKT1—atherosclerosis	6.5e-05	0.0012	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LTA4H—atherosclerosis	6.48e-05	0.00119	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCG8—atherosclerosis	6.48e-05	0.00119	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—atherosclerosis	6.4e-05	0.00118	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APOE—atherosclerosis	6.4e-05	0.00118	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LEP—atherosclerosis	6.4e-05	0.00118	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CAV1—atherosclerosis	6.34e-05	0.00117	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APOA1—atherosclerosis	6.32e-05	0.00116	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ESR1—atherosclerosis	6.11e-05	0.00112	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HMGCR—atherosclerosis	6.04e-05	0.00111	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—F2—atherosclerosis	6.03e-05	0.00111	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CG—atherosclerosis	5.77e-05	0.00106	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—MAPK3—atherosclerosis	5.53e-05	0.00102	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—INS—atherosclerosis	5.47e-05	0.00101	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	5.39e-05	0.000992	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCL2—atherosclerosis	5.38e-05	0.00099	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IGF1—atherosclerosis	5.29e-05	0.000973	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCG1—atherosclerosis	5.12e-05	0.000943	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SERPINE1—atherosclerosis	5.02e-05	0.000924	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—FABP4—atherosclerosis	4.82e-05	0.000887	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LCAT—atherosclerosis	4.82e-05	0.000887	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NOS3—atherosclerosis	4.79e-05	0.000882	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOA4—atherosclerosis	4.73e-05	0.00087	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP7A1—atherosclerosis	4.65e-05	0.000855	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	4.43e-05	0.000815	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP27A1—atherosclerosis	4.29e-05	0.00079	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCL8—atherosclerosis	4.25e-05	0.000782	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	4.23e-05	0.000778	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	4.12e-05	0.000759	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AKT1—atherosclerosis	4.11e-05	0.000756	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALOX5AP—atherosclerosis	4.07e-05	0.000749	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLA2G2A—atherosclerosis	4.07e-05	0.000749	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALOX15—atherosclerosis	4.07e-05	0.000749	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOA2—atherosclerosis	4.07e-05	0.000749	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL6—atherosclerosis	4.04e-05	0.000744	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCG5—atherosclerosis	4.02e-05	0.00074	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	4.02e-05	0.000739	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LPA—atherosclerosis	3.88e-05	0.000715	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MMP9—atherosclerosis	3.85e-05	0.000708	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NFKB1—atherosclerosis	3.8e-05	0.0007	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—BGN—atherosclerosis	3.76e-05	0.000692	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAPK8—atherosclerosis	3.74e-05	0.000688	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	3.73e-05	0.000687	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AKT1—atherosclerosis	3.73e-05	0.000686	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOA5—atherosclerosis	3.72e-05	0.000685	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	3.62e-05	0.000666	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLA2G1B—atherosclerosis	3.58e-05	0.00066	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	3.54e-05	0.000652	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	3.51e-05	0.000646	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	3.5e-05	0.000645	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALOX5—atherosclerosis	3.46e-05	0.000637	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VEGFA—atherosclerosis	3.45e-05	0.000636	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—STAT3—atherosclerosis	3.42e-05	0.000629	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAPK3—atherosclerosis	3.27e-05	0.000601	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	3.2e-05	0.000589	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TGFB1—atherosclerosis	3.17e-05	0.000583	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NAMPT—atherosclerosis	3.1e-05	0.000571	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	3.09e-05	0.000568	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LIPC—atherosclerosis	3.09e-05	0.000568	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOC3—atherosclerosis	3.07e-05	0.000564	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LDLR—atherosclerosis	3.05e-05	0.000561	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CETP—atherosclerosis	2.98e-05	0.000548	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SCARB1—atherosclerosis	2.85e-05	0.000525	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	2.78e-05	0.000511	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HMGCR—atherosclerosis	2.69e-05	0.000495	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	2.43e-05	0.000447	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCA1—atherosclerosis	2.4e-05	0.000442	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6—atherosclerosis	2.39e-05	0.00044	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKT1—atherosclerosis	2.2e-05	0.000405	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HMOX1—atherosclerosis	2.06e-05	0.000379	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOB—atherosclerosis	1.97e-05	0.000363	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTM1—atherosclerosis	1.92e-05	0.000353	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LPL—atherosclerosis	1.88e-05	0.000347	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GPX1—atherosclerosis	1.84e-05	0.000338	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CD36—atherosclerosis	1.79e-05	0.000329	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MTHFR—atherosclerosis	1.7e-05	0.000312	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPARA—atherosclerosis	1.66e-05	0.000306	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AGT—atherosclerosis	1.61e-05	0.000296	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOE—atherosclerosis	1.58e-05	0.00029	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CAV1—atherosclerosis	1.56e-05	0.000288	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOA1—atherosclerosis	1.56e-05	0.000287	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CG—atherosclerosis	1.42e-05	0.000262	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPARG—atherosclerosis	1.37e-05	0.000253	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—INS—atherosclerosis	1.35e-05	0.000248	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALB—atherosclerosis	1.24e-05	0.000227	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NOS3—atherosclerosis	1.18e-05	0.000218	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTGS2—atherosclerosis	1.08e-05	0.000199	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AKT1—atherosclerosis	5.43e-06	0.0001	CbGpPWpGaD
